Oncolytics Biotech (ONCY) News Today $0.55 +0.00 (+0.73%) As of 11:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Oncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours TradesMay 4 at 11:12 AM | nasdaq.comOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of ActionApril 24, 2025 | prnewswire.comAs Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer TreatmentsApril 14, 2025 | baystreet.caOncolytics Biotech Secures $20 Million Funding for Pelareorep DevelopmentApril 10, 2025 | tipranks.comOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni CapitalApril 10, 2025 | prnewswire.comOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic CancersApril 10, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for ONCY FY2027 Earnings?Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.08) per share for the yeMarch 14, 2025 | marketbeat.comLeede Financial Has Positive Outlook of ONCY FY2025 EarningsOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at Leede Financial raised their FY2025 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company wiMarch 14, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Oncolytics BiotechOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst P. Trucchio now forecasts that the companyMarch 13, 2025 | marketbeat.comMaxim Group Issues Pessimistic Forecast for Oncolytics Biotech (NASDAQ:ONCY) Stock PriceMaxim Group lowered their price objective on Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating for the company in a report on Monday.March 11, 2025 | marketbeat.comOncolytics Biotech's (ONCY) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Monday.March 11, 2025 | marketbeat.comRoyal Bank of Canada Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00Royal Bank of Canada lowered their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday.March 11, 2025 | marketbeat.comOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comOncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings ResultsOncolytics Biotech (NASDAQ:ONCY - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01.March 8, 2025 | marketbeat.comOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Down 14.1% in FebruaryOncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 3,050,000 shares, a decrease of 14.1% from the January 31st total of 3,550,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is presently 2.7 days.March 5, 2025 | marketbeat.comOncolytics Biotech (ONCY) to Release Quarterly Earnings on FridayOncolytics Biotech (NASDAQ:ONCY) will be releasing earnings before the market opens on Friday, March 7, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669693)February 28, 2025 | marketbeat.comWorld Cancer Day Sparks Big Questions About Pollution, Genetics, and InnovationFebruary 27, 2025 | baystreet.caUSA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025February 27, 2025 | finanznachrichten.deOncolytics Biotech to Discuss 2024 Financial Results and Operational HighlightsFebruary 25, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational HighlightsFebruary 25, 2025 | prnewswire.comOncolytics Biotech advances pancreatic, anal cancer trialsFebruary 20, 2025 | markets.businessinsider.comUSA News Group: Investors Eye Biotech Sector as Cancer Therapy Market SurgesFebruary 19, 2025 | finanznachrichten.deOncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025February 19, 2025 | prnewswire.comOncolytics provides progress update for pelareorep in pancreatic and anal cancerFebruary 18, 2025 | markets.businessinsider.comOptimism in War on Cancer on the Rise, as Biotech Companies Roll Out More WinsFebruary 18, 2025 | baystreet.caOncolytics making progress in 2025 with regulatory, clinical advancementsFebruary 18, 2025 | markets.businessinsider.comOncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast CancerFebruary 18, 2025 | prnewswire.comShort Interest in Oncolytics Biotech Inc. (NASDAQ:ONCY) Rises By 35.0%Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 3,550,000 shares, a growth of 35.0% from the January 15th total of 2,630,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.0 days.February 17, 2025 | marketbeat.comOncolytics receives noncompliance notification from NasdaqFebruary 14, 2025 | markets.businessinsider.comOncolytics Biotech faces Nasdaq delisting over share priceFebruary 14, 2025 | msn.comOncolytics Biotech Receives Nasdaq Notification for Bid Price DeficiencyFebruary 14, 2025 | tipranks.comOncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyFebruary 14, 2025 | prnewswire.comOncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of AbsenceFebruary 7, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for ONCY FY2024 Earnings?Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for Oncolytics Biotech in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.28) per share for the year, uFebruary 5, 2025 | marketbeat.comBrokers Issue Forecasts for ONCY FY2029 EarningsOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings estimates for Oncolytics Biotech in a research note issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio forecasts that the company will earn $1.10 per share for the yeaFebruary 4, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Oncolytics Biotech (NASDAQ:ONCY)HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research note on Monday.February 3, 2025 | marketbeat.comUSA News Group: Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers SymposiumJanuary 22, 2025 | finanznachrichten.deOncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI SymposiumJanuary 22, 2025 | prnewswire.comRegulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety DataJanuary 15, 2025 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% - Still a Buy?Oncolytics Biotech (NASDAQ:ONCY) Shares Up 3.2% - Still a Buy?January 4, 2025 | marketbeat.comThe Immunotherapy Boom: What It Means for the Future of Cancer TreatmentDecember 26, 2024 | baystreet.caOncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer DataDecember 23, 2024 | prnewswire.comEarly-Onset Cancer Trends Spark Interest in Promising Oncology PipelinesDecember 18, 2024 | baystreet.caOncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI SymposiumDecember 18, 2024 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Shares Down 2.1% - Here's What HappenedOncolytics Biotech (NASDAQ:ONCY) Trading Down 2.1% - Should You Sell?December 13, 2024 | marketbeat.comOncolytics Biotech Inc. (ONC.TO)December 12, 2024 | ca.finance.yahoo.comOncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer CohortDecember 3, 2024 | prnewswire.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCY Media Mentions By Week ONCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCY News Sentiment▼0.590.73▲Average Medical News Sentiment ONCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCY Articles This Week▼11▲ONCY Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Eledon Pharmaceuticals News Today Cardiff Oncology News Today Voyager Therapeutics News Today Alumis News Today Fulcrum Therapeutics News Today Y-mAbs Therapeutics News Today biote News Today Genfit News Today INmune Bio News Today Esperion Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCY) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
